Author: Ken Dropiewski

Medtronic Gains FDA Clearance, CE Mark for LINQ II™ Insertable Cardiac Monitor (ICM)

Next Generation ICM Offers Remote Programming with Improved Longevity and Enhanced Accuracy DUBLIN, July 07, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE (Conformité Européenne) Mark approval for its LINQ II™ insertable cardiac monitor (ICM) with […]

SINOMED® Completes Last Patient Follow-Up of the PIONEER-III Pivotal US and Japanese Trial of the BuMA Supreme® Coronary Drug-Eluting Stent

TIANJIN, China, July 6, 2020 /PRNewswire/ — SINOMED, a developer of innovative neuro- and cardiovascular technologies, announced the completion of the 1-year follow-up in the PIONEER-III, randomized global trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). Once completed, the company plans to submit the data to the U.S. Food and Drug Administration and Japanese Pharmaceuticals […]

Paragonix Technologies Announces Utilization of Paragonix SherpaPak CTS in Complex Heart Transplant Study

New data on successful transplantations for high-risk profile donor hearts presented at the American Transplant Congress CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. announced the presentation of new clinical data at the American Transplant Congress (ATC) on the successful use of the Paragonix SherpaPak™ Cardiac Transport System (CTS) for high-risk donor hearts at the […]

SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators

Integrin A5 may be a new target for intervening in the cell infectious process Findings may lead to the development of precision therapeutic approaches to prevent SARS-CoV-2-cell entry while preserving the functional activity of ACE2 WESTMINSTER and AURORA, Colo., July 07, 2020 (GLOBE NEWSWIRE) — The University of Colorado Anschutz Medical […]

Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules

MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for […]

Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring

ABBOTT PARK, Ill., July 6, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The devices bring new benefits to patients with heart rhythm disorders, including […]

CardieX’s Wearable Partner Blumio Signs Deal with Global Semiconductor Company

SYDNEY, July 6, 2020 /PRNewswire/ — CardieX Limited (ASX: CDX) (CardieX, the Company) announces that its wearables co-development partner, Blumio, Inc, has entered into a significant partnership with global semiconductor company Infineon Technologies AG (Infineon) for the development and commercialization of sensor technology based on Infineons’s radar chip and Blumio’s software and algorithms. CardieX has several […]

Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001

Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001 First patient successfully dosed in cardiomyopathy study Stratford-upon-Avon, UK: July, 6 2019 – Celixir, a privately-owned company discovering and developing life-saving advanced therapies, announces an update to its ongoing clinical programme with lead therapeutic candidate CLXR-001. The first patient was […]